How do we accurately predict the clinical success of in vivo CAR-T therapies before they reach patients? In this webinar, we’ll explore our next-generation mouse models that are transforming preclinical assessment.

We'll delve into cutting-edge strategies for developing CAR-T therapies directly in the body using innovative methods like mRNA/LNP delivery and viral vectors, and discuss why choosing the right models, (ranging from immunodeficient xenografts to advanced humanized strains like NCG, PBMC-NCG, and HSC-NCG), are pivotal in bridging preclinical research to clinical success, enabling precise evaluation of tumor clearance, CAR persistence, cytokine responses and safety. 

Whether you're in oncology or immunology drug development, learn how these models accelerate translation by mimicking human immune dynamics and help researchers develop more effective and safer in vivo CAR-T therapies.

Key topics include:

• Introducing humanized mouse models for translational research

• Exploring oncology-focused mouse models for in vivo CAR-T assessment

• Addressing the challenges and limitations in current preclinical models

Date: Tuesday, February 10, 2025

Time: 8:00 AM PST | 10:00 AM CST | 11:00 AM EST | 5:00 PM CET

Duration: One Hour